Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells

Journal of Urology

Volumn 188, Issue 6, 2012, Pages 2410-2418

  Sato, Akinori ^a   Asano, Takako ^a   Ito, Keiichi ^a   Asano, Tomohiko ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

bortezomib; prostate; prostatic neoplasms; ubiquitinated proteins; vorinostat

Indexed keywords

ANDROGEN RECEPTOR; BORTEZOMIB; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; PROTEIN P21; UBIQUITINATED PROTEIN; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; PYRAZINES; RANDOM ALLOCATION; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY; UBIQUITINATED PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869082464     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.07.108     Document Type: Article

References (26)

1. Y. Liu, Y. Ye Proteostasis regulation at the endoplasmic reticulum: a new perturbation site for targeted cancer therapy Cell Res 21 2011 867
2. B.S. Mann, J.R. Johnson, M.H. Cohen FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma Oncologist 12 2007 1247
3. P. Bali, M. Pranpat, J. Bradner Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors J Biol Chem 280 2005 26729
4. W. Fiskus, Y. Ren, A. Mohapatra Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90 Clin Cancer Res 13 2007 4882
5. D. Bradley, D. Rathkopf, R. Dunn Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium Cancer 115 2009 5541
6. C. Naujokat, O. Sezer, H. Zinke Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells Eur J Haematol 65 2000 221
7. M. Frezza, H. Yang, Q.P. Dou Modulation of the tumor cell death pathway by androgen receptor in response to cytotoxic stimuli J Cell Physiol 226 2011 2731
8. T. Ikezoe, Y. Yang, T. Saito Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells Cancer Sci 95 2004 271
9. C.S. Mitsiades, N.S. Mitsiades, C.J. McMullan Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications Proc Natl Acad Sci U S A 101 2004 540
10. M.J. Morris, W.K. Kelly, S. Slovin A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer J Urol 178 2007 2378
11. Q.L. Zhang, L. Wang, Y.W. Zhang The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis Leukemia 23 2009 1507
12. A. Sato, T. Asano, K. Ito Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically BJU Int 109 2012 1258
13. D. Yin, H. Zhou, T. Kumagai Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM) Oncogene 24 2005 344
14. L.V. Pham, A.T. Tamayo, L.C. Yoshimura Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis J Immunol 171 2003 88
15. D. Yin, J.M. Ong, J. Hu Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo Clin Cancer Res 13 2007 1045
16. V.M. Richon, T.W. Sandhoff, R.A. Rifkind Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation Proc Natl Acad Sci U S A 97 2000 10014
17. H. Matta, P.M. Chaudhary The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells Cancer Biol Ther 4 2005 77
18. E.G. Mimnaugh, W. Xu, M. Vos Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity Mol Cancer Ther 3 2004 551
19. M. Boccadoro, G. Morgan, J. Cavenagh Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy Cancer Cell Int 5 2005 18
20. J.B. Almond, G.M. Cohen The proteasome: a novel target for cancer chemotherapy Leukemia 16 2002 433
21. E.P. Jane, D.R. Premkumar, I.F. Pollack Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway Mol Cancer Ther 10 2011 198
22. D.S. Hill, S. Martin, J.L. Armstrong Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma Clin Cancer Res 15 2009 1192
23. P.A. Wade Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin Hum Mol Genet 10 2001 693
24. A. Sato, T. Asano, A. Horiguchi Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells Urology 76 2010 764.e7
25. X. Zhou, X.Y. Yang, N.C. Popescu Preclinical evaluation of combined antineoplastic effect of DLC1 tumor suppressor protein and suberoylanilide hydroxamic acid on prostate cancer cells Biochem Biophys Res Commun 420 2012 325
26. A. Badros, A.M. Burger, S. Philip Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma Clin Cancer Res 15 2009 5250